Company intelligence / Profile preview

FluidDx Health

Salt Lake City, Utah, United Statesfluidscienceltd.com ↗

Ownership: Private
Employees: ~24
Development stage: Other

Overview

The company’s flagship GPX Embolic Device has completed a successful multi-center clinical trial as a multi-use embolic in 2023 and focuses on procedures requiring deep distal penetration. The device offers simple preparation, rapid delivery, high radiopacity during use, and does not require special mixing or delivery systems. It remains investigational with no market clearance yet.

Therapeutic areas: HematologyCardiovascularOncologyNeurology
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on FluidDx Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FluidDx Health.

Explore the full profile